State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

State Street Corp lessened its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,485,156 shares of the biopharmaceutical company’s stock after selling 173,932 shares during the quarter. State Street Corp’s holdings in Celldex Therapeutics were worth $84,470,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. KBC Group NV boosted its position in Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Celldex Therapeutics in the 2nd quarter worth $76,000. Los Angeles Capital Management LLC boosted its position in shares of Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 638 shares in the last quarter. Quest Partners LLC boosted its position in shares of Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 6,879 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 1,504 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CLDX shares. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, November 20th. The Goldman Sachs Group started coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Finally, Citigroup started coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $62.25.

Insider Buying and Selling at Celldex Therapeutics

In related news, CEO Anthony S. Marucci acquired 11,500 shares of Celldex Therapeutics stock in a transaction on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.80% of the company’s stock.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $26.20 on Tuesday. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -10.19 and a beta of 1.57. The business has a fifty day moving average of $27.19 and a 200 day moving average of $33.58. Celldex Therapeutics, Inc. has a 1 year low of $22.93 and a 1 year high of $53.18.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.